A comparative study to evaluate the safety and immunogenicity of two lots of haemophilus influenzae type-b conjugate vaccine manufactured at different scales

Vaccine

Volumn 29, Issue 33, 2011, Pages 5363-5367

  Hirve, Siddhivinayak ^a   Bavdekar, Ashish ^b   Juvekar, Sanjay ^a   Agarwal, Dhiraj ^a   Barde, Prajakt ^c   Mangrule, Somnath ^c   Patwardhan, Moreshwar ^c   Pandit, Anand ^b   Kulkarni, Prasad S ^c  

^a Shirdi Sai Baba Rural Hospital   (India)

^b KEM HOSPITAL   (India)

^c Serum Institute of India   (India)

Author keywords

Anti PRP antibodies; Haemophilus influenzae type B; Industrial scale; SII HibPRO; Small scale; Vaccine

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B TETANUS TOXOID CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; ORAL POLIOMYELITIS VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE ANTIBODY; TETANUS TOXOID; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGENICITY; INDUSTRIAL SCALE MANUFACTURE; INFANT; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; SCALE UP; SEROPROTECTION; SIDE EFFECT; SMALL SCALE MANUFACTURE; VACCINATION; VACCINE PRODUCTION;

ANTIBODIES, BACTERIAL; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INJECTIONS, INTRAMUSCULAR; MALE; POLIOVIRUS VACCINE, ORAL; POLYSACCHARIDES; TETANUS TOXOID; VACCINATION; VACCINES, CONJUGATE;

EID: 79960375050     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.081     Document Type: Article

References (17)

1. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006, 81:445-452.
2. Lolekha S., Cooksley G., Chan V., Isahak I., Ismael S., John J., et al. A review of Hib epidemiology in Asia. Southeast Asian J Trop Med Public Health 2000, 31(4):650-657.
3. Singh M., Chaudhry M.A., Yadava J.N., Sanyal S.C. The spectrum of antibiotic resistance in human and veterinary isolates of Escherichia coli collected from 1984-86 in northern India. J Antimicrob Chemother 1992, 29(2):159-168.
4. Levine O.S., Wenger J.D. Defining the burden of Hib disease in India. Indian Pediatr 2002, 39(1):5-11.
5. IAP Guidebook on Immunization. [cited 02.02.08]. http://www.iapindia.org/.
6. Data on file. Serum Institute of India Limited, Pune.
7. Jones B., Jarvis P., Lewis J.A., Ebbutt A.F. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996, 313(7048):36-39.
8. Decker M.D., Edwards K.M., Bradley R., Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992, 120(2 Pt 1):184-189.
9. Phadke M.A., Kulkarni M.V., Sovani V.B., Lokeshwar M.R., Venkataraman R. Immunogenicity study of Haemophilus influenzae type B conjugate vaccine in Indian infants. Indian Pediatr 1997, 34(9):779-783.
10. Mulholland E.K., Byass P., Campbell H., Fritzell B., Greenwood A.M., Todd J., et al. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants. Ann Trop Paediatr 1994, 14(3):183-188.
11. Panpitpat C., Thisyakorn U., Chotpitayasunondh T., Furer E., Que J.U., Hasler T., et al. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine. Bull World Health Organ 2000, 78(3):364-371.
12. Matjila M.J., Phohu T.C., Banzhoff A., Viviani S., Hoosen A.A., Bianchini M., et al. Safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines. S Afr Med J 2004, 94(1):43-46.
13. Marshall H., McIntyre P., Roberton D., Dinan L., Hardt K. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic. Int J Infect Dis 2009.
14. Capeding M.R., Nohynek H., Pascual L.G., Kayhty H., Sombrero L.T., Eskola J., et al. The immunogenicity of three Haemophilus influenzae type B conjugate vaccines after a primary vaccination series in Philippine infants. Am J Trop Med Hyg 1996, 55(November (5)):516-520.
15. Käyhty H., Eskola J., Peltola H., Rönnberg P.R., Kela E., Karanko V., et al. Antibody responses to four Haemophilus influenzae type b conjugate vaccines. Am J Dis Child 1991, 145(February (2)):223-227.
16. Kim K.H., Lee H., Chung E.H., Kang J.H., Kim J.H., Kim J.S., et al. Immunogenicity and safety of two different Haemophilus influenzae type b conjugate vaccines in Korean infants. J Korean Med Sci 2008, 23(6):929-936.
17. Punjabi N.H., Richie E.L., Simanjuntak C.H., Harjato S.J., Wangsasapura F., Arjoso S., et al. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertusis vaccine (DTP-Hib), in Indonesian infants. Vaccine 2006, 24(11):1776-1785.